MedTrace Logo

Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide

NCT03065790 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2021-06-04

No results posted yet for this study

Summary

Adult patients with non-Hodgkin lymphoma who will be treated with lenalidomide will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated response and long term outcomes.

Conditions

Interventions

DIAGNOSTIC_TEST

2-Deoxy-2-[18F]fluoro-D-glucose (FDG)

2-Deoxy-2-\[18F\]fluoro-D-glucose (FDG)

Sponsors & Collaborators

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • Michael Farwell, MD · Abramson Cancer Center at Penn Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-06
Primary Completion
2021-04-28
Completion
2021-04-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03065790 on ClinicalTrials.gov